CORDIS
EU research results

CORDIS

English EN
Soraprazan - a new regenerative therapy for Stargardt's disease

Soraprazan - a new regenerative therapy for Stargardt's disease

Objective

Soraprazan – a new regenerative therapy for Stargardt’s disease
Abnormal accumulation of lipofuscin in the RPE cells is a hallmark in Stargardt's disease. As lipofuscin cannot be removed from the RPE cells in the eyes neither spontaneously nor with existing therapies, the accumulation of lipofuscin in the RPE cells of the eyes results in the degradation of the RPE cells and consequently in worsening of visual acuity and could lead to blindness. Soraprazan was able to show removal of lipofuscin in RPE cells. Aim of the phase II trial in this project is to evaluate savety and efficacy or orally taken Soraprazan treatment compared to placebo.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Address

Geschwister-Scholl-Platz
72074 Tuebingen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 467 500

Participants (6)

Sort alphabetically

Sort by EU Contribution

Expand all

KATAIRO GMBH

Germany

EU Contribution

€ 2 705 000

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 319 500

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 242 362,50

UNIVERSITY OF SOUTHAMPTON

United Kingdom

EU Contribution

€ 252 500

OSPEDALE SAN RAFFAELE SRL

Italy

EU Contribution

€ 244 312,50

SMERUD MEDICAL RESEARCH INTERNATIONAL AS

Norway

EU Contribution

€ 1 561 250

Project information

Grant agreement ID: 779317

Status

Ongoing project

  • Start date

    1 December 2017

  • End date

    30 November 2021

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 792 425

  • EU contribution

    € 5 792 425

Coordinated by:

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany